Zusammenfassung
Nach wie vor stellt die chirurgische Therapie die Basis der Behandlung von Patienten mit einem Kolonkarzinom dar. Multimodale Therapiekonzepte werden derzeit in der adjuvanten Therapie und zunehmend in der systemischen Therapie von Patienten mit primär inoperablen Lebermetastasen zum Erreichen einer sekundären Operabilität nach Vortherapie als therapeutischer Standard angewendet. Im Rahmen der Behandlung des metastasierten Kolonkarzinoms sind interdisziplinäre multimodale Therapiekonzepte derzeit ebenfalls etabliert. Offene Fragen existieren bezüglich der Abfolge der palliativen systemischen Therapien und ihrer Kombination mit lokal ablativen Verfahren.
Abstract
Surgical therapy is still the basis of therapy of patients with colon carcinoma. Multimodal therapeutical concepts are presently applied as a therapeutical standard in the adjuvant therapy and increasingly in the systemic therapy of patients with primarily inoperable metastases of the liver to reach a secondary operability. Interdisciplinary multimodal therapeutical concepts are even accepted within the therapy of metastasized colon carcinomas. There are still unanswered questions regarding sequences of palliative systemic therapies and their combinations with local ablative methods.
Schlüsselwörter
Kolonkarzinom - multimodale Therapie - adjuvante Chemotherapie - palliative Chemotherapie - lokoregionäre Therapie
Key words
colon carcinoma - multimodal therapy - adjuvant chemotherapy - palliative chemotherapy - locoregionary therapy
Literatur
-
1
Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert H, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A.
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial.
J Clin Oncol.
2003;
21
2896-2903
-
2
Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky R L.
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Ann Oncol.
2002;
13
566-575
-
3
Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.
Lancet.
2000;
355
1588-1596
-
4
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E.
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
N Eng J Med.
2004;
351
337-345
-
5
de Gramont A, Bosset J F, Milan C, Rougier P, Bouche O, Etienne P L, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L.
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
J Clin Oncol.
1997;
15
808-815
-
6
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
J Clin Oncol.
2000;
18
2938-2947
-
7 Deutsche Krebsgesellschaft e. V. .Kurzgefasste Interdisziplinäre Leitlinie 2004. 4. Aufl. W. Zuckschwerdt Verlag, München, Wien, New York 2004; 159-160
-
8
Douillard J Y, Cunningham D, Roth A D, Navarro M, James R D, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Grnia G, Awad L, Rougier P.
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Lancet.
2000;
355
1041-1047
-
9
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.
J Clin Oncol.
1998;
16
301-308
-
10
Fey M F.
Die adjuvante medikamentöse Therapie des Kolon-Karzinoms.
Schweiz Med Wochenschr.
2000;
130
1760-1765
-
11
Fong Y, Fortner J, Sun R L, Brennan M F, Baumgart L H.
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1 001 consecutive cases.
Ann Surg.
1999;
230
309-318
-
12
Gastinger I, Marusch F.
Evidence-based Chirurgie des Kolonkarzinoms.
Zentralbl Chir.
2001;
126
283-288
-
13
Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset J L, Levi F.
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
Ann Oncol.
1999;
10
663-669
-
14
Grothey A, Sargent D, Goldberg R M, Schmoll H J.
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
J Clin Oncol.
2004;
7
1209-1214
-
15
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F.
Bevacizumab (rhuMAb VEGF) to bolus IFL in the first-line treatment of patients with metastatic colorectal cancer: Results of a randomized phase III trial.
N Engl J Med.
2004;
350
2335-2342
-
16
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer.
Lancet.
1995;
345
939-944
-
17
Kabbinavar F, Hurwitz H I, Fehrenbacher L, Meropol N J, Novotny W F, Lieberman G, Griffing S, Bergsland E.
Phase II randomized trial comparing bevacizumab plus fluouracil (FU)/Leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
JCO.
2003;
21
60-65
-
18
Köckerling F, Reymond M A, Altendorf-Hofmann A, Dworak O, Hohenberger W.
Influence of Surgery on metachronous distant metastases and survival in rectal cancer.
J Clin Oncol.
1998;
16
324-329
-
19
Köhne C H, Van Cutsem E, Wils J A, Bokemeyer C, El-Sarafi M, Lutz M, Lorenz M, Anak O, Genicot B, Nordlinger B.
Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986.
Proc Am Soc Clin Oncol.
2003;
22
154
-
20 Krebs in Deutschland. 4. überarbeitete aktualisierte Ausgabe. Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister, Saarbrücken 2004; 28-32
-
21
Link K H, Mörschel M, Sagban T A, Appelt V, Holtappels M, Tischbirek K.
Chirurgie und multimodale Therapie des Kolonkarzinoms: Evidenzbasis?.
Chir Gastroenterol.
2004;
20
39-54
-
22
Merkel S, Wein A, Gunther K, Papadopoulos T, Hohenberger W, Hermanek P.
High-risk groups of patients with Stage II colon carcinoma.
Cancer.
2001;
15
1435-1443
-
23
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.
J Clin Oncol.
1992;
10
896-903
-
24
Moertel C G, Fleming T R, Macdonald J S, Haller D G, Laurie J A, Tangen C M, Ungerleider J S, Emerson W A, Tormey D C, Glick J H.
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.
Ann Intern Med.
1995;
122
321-326
-
25 National Comprehensive Cancer Network Guidelines on Treatment of Colon Cancer. available online at www.nccn.org/physician_gls/f_guidelines.html (Accessed 8/10/04)
-
26 National Comprehensive Cancer Network Guidelines of Treatment of Colon Cancer. www.nccn.org/physician_gls/f_guidelines.html
-
27
NIH consensus conference .
Adjuvant therapy for patients with colon and rectal cancer.
JAMA.
1990;
264
1444
-
28
Petrowsky H, Gonen M, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, Encke A, Blumgart L, Fong Y.
Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis.
Ann Surg.
2002;
235
863-871
-
29
Piedbois P, Michelis S.
Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: An updated meta-analysis based on 2 751 patients.
Proc Am Soc Clin Oncol.
2003;
22
156
-
30
Rothenberg M L, Meropol N J, Poplin E A, van Cutsem E, Wadler S.
Mortality associatet with irinotecan plus fluorouracil/leucovorin: Summary findings of an independent panel.
J Clin Oncol.
2001;
19
3801-3807
-
31
Rougier P, Sahmond T, Nitti D, Curran D, Doci R, de Waek B. for the EORTC GIT Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia and the Japanese Foundation for Cancer Research .
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial.
Lancet.
1998;
351
1677-1681
-
32
Saini A, Norman A R, Cunningham D, Chau I, Hill M, Tait D, Hickish T, Iveson T, Lofts F, Jodrell D, Ross P J, Oates J.
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 month of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
Br J Cancer.
2003;
88
1859-1865
-
33
Saltz L B, Cox J V, Blanke C, Rosen L S, Fehrenbacher L, Moore M J, Maronn J A, Ackland J P, Locker P K, Pirotta N, Elfring G L, Miller L L.
Irinotecan plus fluouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
N Engl J Med.
2000;
343
905-914
-
34
Saltz L B, Niedzwicki D, Hollis D, Goldberg R M, Hantel A, Thomas P, Fields A LA, Larver G, Mayer R J.
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin allone (FL) in stage III colon cancer (intergroup trial CALGB C 89803) (abstract 3500).
Proc Am Soc Clin Oncol.
2004;
23
2455
-
35
Scheithauer W, McKendrick J, Begbie S, Borner M, Burns W I, Burris H A, Cassidy J, Jodrell D, Koralewski P, Levine E L, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C.
Oral capecitabine as an alternative to i. v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Ann Oncol.
2003;
14
1735-1743
-
36
Schlag P M.
Pathomorphologie und Chirurgie-Standards beim kolorektalen Karzinom.
Onkologe.
1998;
4 (Suppl 1)
23-27
-
37
Scott K W, Grace R H.
Detection of lymphe node metastases in colorectal cancer before and after fat clearance.
Br J Surg.
1989;
76
1165-1167
-
38
Seufferlein T, Lutz M P, Adler G.
Multimodale Therapiekonzepte beim Kolonkarzinom.
Internist.
2003;
44
322-335
-
39
Seymour M.
Optimizing the use and sequenzing of fluorouracil, irinotecan and oxaliplatin in advanced colorectal cancer (ACRC): The UK MRC FOCUS (CR08) trial.
Ann Onc.
2004;
15 (Suppl 3)
iii 2 (5IN)
-
40
Stocchi L, Nelson H, Sargant D J, O'Connell M J, Tepper J E, Krook J E, Bart R.
Impact of surgical and pathologic variables in rectal cancer: A United States Community and cooperative group report.
J Clin Oncol.
2001;
19
3895-3902
-
41
Swiss Group for Clinical Cancer Research (SAKK) .
Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer.
Lancet.
1995;
345
349-353
-
42
Taylor I, Machin D, Muller M, Trotter G, Cooke T, West C.
A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer.
Br J Surg.
1985;
72
359-363
-
43
Willett C G, Goldberg S, Skellito P C, Grossbard M, Clark J, Fung C, Proulx G, Dely M, Kaufmann D S.
Does postoperative irradiation play a role in adjuvant therapy of stage T4 colon cancer?.
Cancer J Sci Am.
1999;
514
242-247
-
44
Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham D L, Bear H D, Atkins J N, Dimitrov N V, Glass A G, Fisher E R, Fisher B.
Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.
J Clin Oncol.
1999;
17
3553-3559
Priv.-Doz. Dr. med. J. Fahlke
Klinik für Allgemein-, Viszeral- und Gefäßchirurgie · Otto-von-Guericke-Universität
Leipziger Str. 44
39120 Magdeburg
Phone: 03 91/1 56 89
Email: Joerg.Fahlke@medizin.uni-magdeburg.de
